News coverage about Natus Medical (NASDAQ:BABY) has trended somewhat negative recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Natus Medical earned a daily sentiment score of -0.03 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.0606434709178 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Shares of Natus Medical (NASDAQ BABY) opened at $28.95 on Tuesday. The company has a quick ratio of 3.36, a current ratio of 4.21 and a debt-to-equity ratio of 0.36. Natus Medical has a 52 week low of $28.40 and a 52 week high of $43.60. The stock has a market cap of $901.91, a price-to-earnings ratio of -321.63 and a beta of 0.84.

Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The business had revenue of $122.60 million during the quarter, compared to analyst estimates of $122.41 million. During the same quarter in the previous year, the business earned $0.39 EPS. Natus Medical’s quarterly revenue was up 34.9% compared to the same quarter last year. research analysts forecast that Natus Medical will post 1.64 earnings per share for the current year.

Several research firms have recently commented on BABY. Zacks Investment Research cut shares of Natus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. BidaskClub lowered shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, January 6th. Finally, William Blair lowered shares of Natus Medical from an “outperform” rating to a “market perform” rating in a research note on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $46.50.

In other Natus Medical news, Director William M. Moore sold 5,000 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $41.01, for a total transaction of $205,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Dong Chune Christopher Chung sold 12,642 shares of the business’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $42.91, for a total transaction of $542,468.22. Following the transaction, the vice president now directly owns 141,414 shares of the company’s stock, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & international copyright and trademark law. The legal version of this piece can be accessed at https://www.watchlistnews.com/somewhat-critical-media-coverage-somewhat-unlikely-to-impact-natus-medical-baby-share-price/1809062.html.

Natus Medical Company Profile

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Insider Buying and Selling by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.